Enveda Biosciences secures $311M to advance nature-derived AI drug discovery

Enveda Biosciences, a biotechnology company leveraging artificial intelligence to identify therapeutic compounds from the natural world, has successfully closed a $311 million funding round. This latest capital injection brings the company's valuation to $2 billion. The startup utilizes a proprietary AI platform to analyze the chemical structures of plants and natural sources, aiming to accelerate the development of novel drugs. Currently, Enveda is focused on advancing its pipeline into clinical trials, with specific efforts directed toward treatments for dermatological conditions and therapies designed to maintain weight loss results following the cessation of GLP-1 receptor agonists. This significant investment underscores the growing intersection of machine learning and drug discovery, as investors continue to back platforms that promise to shorten the time and cost associated with bringing new pharmaceutical products to market.